Lake Forest, CA, June 10, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that it has been selected by Lynden International (“Lynden”) as its preferred provider to support cold chain clinical trial logistics for underrepresented diseases in Africa.
Cryoport’s comprehensive cryogenic logistics solutions will complement Lynden’s cold chain capabilities in support of its shipments of temperature sensitive materials for ongoing clinical trials in Africa. Cryoport’s solutions ensure that the integrity of shipments and content are maintained and enable more efficient results through greater safety and speed of delivery. Cryoport’s global network allows shipments to securely reach remote locations that are part of this clinical trial.
Lynden International is a full-service domestic and international freight forwarder with over 50 offices worldwide, including the United States, Micronesia, Canada, Mexico, Brazil, Russia and the Russian Far East. Lynden serves as a trusted partner to a wide variety of companies in varying industries including healthcare and pharmaceuticals.
Jerrell Shelton, Chief Executive Officer of Cryoport, commented, “We are pleased with the opportunity to expand Lynden’s capabilities with our validated cryogenic logistics solutions. We have great experience in clinical trial logistics and look forward to working with Lynden in furthering clinical trial work in Africa for underrepresented diseases. Our best-in-class cryogenic logistics solutions are a key component to providing the worldwide access that is required by the life science industry to successfully conduct clinical trials around the globe.”
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.Investor Contacts:
Todd Fromer / Garth Russell
firstname.lastname@example.org / email@example.com
P: 1 212-682-6300